The <i>Addiction</i> archive
 The <i>Addiction</i> archive

Addiction web site. Opens new Window

Effectiveness bank home page. Opens new window Collection
The Addiction archive

Analyses of articles in the journal Addiction published by our partner the Society for the Study of Addiction starting with the most recently published article, totalling today 74 documents.

Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents



STUDY 2018 HTM file
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom

Hickman M., Steer C., Tilling K. et al.
Addiction: 2018, 113(8), p. 1461–1476.
Buprenorphine may be associated with a lower risk of mortality than methadone among people engaged in opioid substitution treatment – but is the pattern of short treatment duration in the UK preventing maximal impact at a population level?

REVIEW 2018 HTM file
Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis

Rose A.K., Jones A.
Addiction: 2018, 113(8), p. 1396–1406.
With patchy evidence of the effectiveness of baclofen, and serious concerns about the medication’s safety, is it ‘premature’ for the muscle-relaxant to be prescribed as a treatment for alcohol use disorders?

STUDY 2018 HTM file
Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings – what is required to achieve the WHO’s HCV elimination targets?

Ward Z., Platt L., Sweeney S. et al.
Addiction: 2018, 113, p. 1727–1738.
What would it take for the UK to meet the World Health Organization’s target of a 90% reduction in hepatitis C by 2030? According to projections in three diverse areas, current levels of harm reduction services are averting a great deal of transmission, and adding only moderate rates of treatment for hepatitis C would put Britain on course to achieve the elimination target.

STUDY 2017 HTM file
Does paying service providers by results improve recovery outcomes for drug misusers in treatment in England?

Jones A., Pierce M., Sutton M. et al.
Addiction: 2017, 113(2), p. 279–286.
Substance use treatment commissioned on a payment-by-results basis in England has been linked to higher rates of in-treatment abstinence and non-injecting than other commissioning models, but lower rates of treatment initiation and completion. Is this enough to support the policy?

REVIEW 2017 HTM file
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate

Palpacuer C., Duprez R., Huneau A. et al.
Addiction: 2017, in press.
In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification, extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none was there high quality evidence.

STUDY 2017 HTM file
The impacts of minimum alcohol pricing on alcohol attributable morbidity in regions of British Colombia, Canada with low, medium and high mean family income

Zhao J., Stockwell T.
Addiction: 2017, 112, p. 1942–1951.
Minimum price increases of alcoholic beverages in a Canadian province between 2002 and 2013 set the stage for a real-word study of minimum unit pricing. Reductions in alcohol-related hospital admissions, particularly in lower income areas, tentatively suggest that low income regions may experience the greatest health benefits of such a policy.

STUDY 2016 HTM file
Effectiveness of Scotland’s National Naloxone Programme for reducing opioid-related deaths: a before (2006–10) versus after (2011–13) comparison

Bird S.M., McAuley A., Perry S. et al.
Addiction: 2016, 111(5), p.883–891.
In 2011 Scotland became the first country to fund a national policy of distributing the opiate-blocker naloxone to prevent deaths involving opiate-type drugs. According to this evaluation it did prevent deaths where the effect was most likely to be seen – in the weeks after release from prison.

REVIEW 2016 HTM file
Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria

McDonald R., Strang J.
Addiction: 2016, 111, p. 1177–1187.
How confident can we be that take-home naloxone programmes are effective without the ‘gold standard’ randomised trial? Judged against nine criteria for establishing the presumption of causality, evidence that the provision of naloxone reduces overdose-related deaths among opioid users.

STUDY 2015 HTM file
The Public Health Responsibility deal: has a public-private partnership brought about action on alcohol reduction?

Knai C., Petticrew M., Durand M.A. et al.
Addiction: 2015, 1000(8), p. 1217–1225.
At the heart of the UK government’s alcohol strategy are ‘Responsibility Deal’ pledges made by alcohol companies, but rather than being prompted by the deal, this report says actions committed to were usually already done or underway. Other sources suggest the process helped forestall a more effective measure – a minimum per unit price for alcohol.

STUDY 2015 HTM file
The impact of paying treatment providers for outcomes: difference-in-differences analysis of the ‘payment by results for drugs recovery’ pilot

Mason T., Sutton M., Whittaker W. et al
Addiction: 2015, 110(7), p. 1120–1128.
A flagship drug treatment policy initiative appears to have backfired in England, where the government’s pilot payment-by-results schemes seem to have led to fewer successful completions of treatment and more prospective patients declining treatment.


Select search results page

NEXT 1 2 3 4 5 6 7 8